Trials / Completed
CompletedNCT01637194
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Fox Chase Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase I trial studies the side effects and best dose of cetuximab when given together with everolimus in treating patients with metastatic or recurrent colon cancer or head and neck cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cetuximab together with everolimus may be an effective treatment for colon cancer or head and neck cancer
Detailed description
PRIMARY OBJECTIVES: I. Determine the safety, dose-limiting toxicity and maximum tolerated dose of daily RAD001 (everolimus) when given in combination with a fixed dose of weekly cetuximab in patients with solid tumors. SECONDARY OBJECTIVES: I. Determine whether a pharmacokinetic interaction exists between RAD001 and CETUXIMAB in patients treated with this regimen. II. Determine preliminary clinical evidence of anti-tumor activity by time to progression and Response Evaluation Criteria in Solid Tumors (RECIST) criteria with this regimen. III. Determine the association between clinical outcomes and biologic markers that may predict sensitivity of a tumor in patients treated with this regimen. IV. Determine the pharmacodynamic effects of this regimen on post-therapy tumor and/or skin specimens. OUTLINE: This is a dose-escalation study of everolimus. Patients receive everolimus orally (PO) once daily (QD) on days -14 and then 1-28. Patients also receive cetuximab intravenously (IV) over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 2 months for at least 1 year.
Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Recurrent Basal Cell Carcinoma of the Lip
- Recurrent Colon Cancer
- Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Lymphoepithelioma of the Nasopharynx
- Recurrent Lymphoepithelioma of the Oropharynx
- Recurrent Metastatic Squamous Neck Cancer With Occult Primary
- Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Recurrent Mucoepidermoid Carcinoma of the Oral Cavity
- Recurrent Salivary Gland Cancer
- Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Recurrent Squamous Cell Carcinoma of the Larynx
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Recurrent Squamous Cell Carcinoma of the Nasopharynx
- Recurrent Squamous Cell Carcinoma of the Oropharynx
- Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Recurrent Verrucous Carcinoma of the Larynx
- Recurrent Verrucous Carcinoma of the Oral Cavity
- Stage IV Adenoid Cystic Carcinoma of the Oral Cavity
- Stage IV Basal Cell Carcinoma of the Lip
- Stage IV Lymphoepithelioma of the Nasopharynx
- Stage IV Lymphoepithelioma of the Oropharynx
- Stage IV Mucoepidermoid Carcinoma of the Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Hypopharynx
- Stage IV Squamous Cell Carcinoma of the Larynx
- Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
- Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Stage IV Squamous Cell Carcinoma of the Oropharynx
- Stage IV Verrucous Carcinoma of the Larynx
- Stage IV Verrucous Carcinoma of the Oral Cavity
- Stage IVA Colon Cancer
- Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Stage IVA Salivary Gland Cancer
- Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IVB Colon Cancer
- Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Stage IVB Salivary Gland Cancer
- Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity
- Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity
- Stage IVC Salivary Gland Cancer
- Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Tongue Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | everolimus | Given PO |
| BIOLOGICAL | cetuximab | Given IV |
| OTHER | pharmacological study | Correlative studies |
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2012-07-11
- Last updated
- 2012-07-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01637194. Inclusion in this directory is not an endorsement.